LabCorp
clinical laboratory company
LH NYSE
ISIN US50540R4092 SEC CIK 920148 LEI 549300CDU4WF6Q2YMS76
Follow LabCorp
Weekly email: filings, results
Revenue, last quarter
$3.8B
+6.9% vs same quarter last year
Net income
$262.8M
+0.7% vs same quarter last year
EPS, diluted
$3.22
+3.2% vs same quarter last year
Operating cash flow
$563.8M
+45.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $14B | $877M |
| FY24 | $13B | $746M |
| FY23 | $12.2B | $418M |
| FY22 | $11.9B | $1.3B |
| FY21 | $13.1B | $2.4B |
| FY20 | $14B | $1.6B |
| FY19 | $11.6B | $823.8M |
| FY18 | $11.3B | $883.7M |
| FY17 | $10.3B | $1.2B |
| FY16 | $9.6B | $711.8M |
| FY15 | $8.7B | $437.6M |
| FY14 | $6B | $511.2M |
| FY13 | $5.8B | $573.8M |
| FY12 | $5.7B | $583.1M |
| FY11 | $5.5B | $519.7M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 28.8% | 9.9% | 6.3% |
| FY24 | 27.9% | 8.4% | 5.7% |
| FY23 | 27.7% | 6% | 3.4% |
| FY22 | 31.3% | 12.1% | 10.8% |
| FY21 | 38% | 23.2% | 18.1% |
| FY20 | 35.4% | 17.5% | 11.1% |
| FY19 | 28.1% | 11.5% | 7.1% |
| FY18 | 28% | 11.7% | 7.8% |
| FY17 | 30% | 12.7% | 11.9% |
| FY16 | 29.9% | 13.3% | 7.5% |
| FY15 | 33.4% | 11.5% | 5% |
| FY14 | 36.6% | 15.1% | 8.5% |
| FY13 | 38.3% | 17.1% | 9.9% |
| FY12 | 39.7% | 18% | 10.3% |
| FY11 | 41% | 17.1% | 9.4% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $1.2B |
| FY24 | $1.1B |
| FY23 | $874.1M |
| FY22 | $1.5B |
| FY21 | $2.7B |
| FY20 | $1.8B |
| FY19 | $1B |
| FY18 | $925.6M |
| FY17 | $1.2B |
| FY16 | $918.2M |
| FY15 | $726.6M |
| FY14 | $535.5M |
| FY13 | $616.5M |
| FY12 | $667.6M |
| FY11 | $709.9M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $240.7M | $450M |
| FY24 | $243.1M | $250.1M |
| FY23 | $254M | $1B |
| FY22 | $195.2M | $1.1B |
| FY21 | - | $1.7B |
| FY20 | - | $100M |
| FY19 | - | $450M |
| FY18 | - | $700M |
| FY17 | - | $338.1M |
| FY16 | - | $43.9M |
| FY15 | - | $0 |
| FY14 | - | $269M |
| FY13 | - | $1B |
| FY12 | - | $516.5M |
| FY11 | - | $643.9M |
- LabCorp
- Healthcare median
Show the numbers
| Year | LabCorp | Healthcare median |
|---|---|---|
| FY25 | 6.3% | −30.6% |
| FY24 | 5.7% | −47% |
| FY23 | 3.4% | −58% |
| FY22 | 10.8% | −80.4% |
| FY21 | 18.1% | −71.9% |
| FY20 | 11.1% | −62.2% |
| FY19 | 7.1% | −46.3% |
| FY18 | 7.8% | −49.6% |
| FY17 | 11.9% | −45.9% |
| FY16 | 7.5% | −36% |
| FY15 | 5% | −38.4% |
| FY14 | 8.5% | −35.5% |
| FY13 | 9.9% | −37.1% |
| FY12 | 10.3% | −29.1% |
| FY11 | 9.4% | −27.9% |